Programmed death (PD) ligand 1 (PD-L1)/PD1 and cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have been used in multiple malignancies, whereas crucial molecules able to disturb other coinhibitory signaling pathways are under investigation (Longo et al., 2019). Here, CTLA4 is linked to cancer.